Treatment Approaches for Resectable Stage-III NSCLC in the Adjuvant Setting

Prior data from the STRESS-LUNG-1 trial introduced emotional distress as a “psycho-biomarker” for immunotherapy efficacy in non–small cell lung cancer.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Phase 2b findings demonstrate improved 2-year survival outcomes with OST-HER2 compared with historical control data.

Zongertinib is now approved by the FDA for patients with nonsquamous NSCLC with HER2 TKD activating mutations.